Asco 2019 – not a Marker of excellence
Marker Therapeutics yesterday narrowly avoided becoming the first casualty of this year’s Asco. The group quietly slipped into an SEC filing that the conference had rejected an abstract covering its MAPP T-Cell Therapy in pancreatic cancer, initially prompting an 11% share price fall, but after some sellside firefighting the stock ended the day off only 4%. As far as Asco abstracts that have been accepted go, only their titles were unveiled yesterday, but already some will have piqued investors’ interest. Mirati bulls will nervously await Amgen’s first phase I data on the KRAS inhibitor AMG 510, billed as best in class, while Roche’s entrectinib, awaiting US approval for NTRK fusion-positive tumours and Ros1-mutated NSCLC, features in a study in children with mutated CNS cancers that has been selected for inclusion in the meeting’s press programme. Meanwhile, investors looking at the Celgene contingent value rights (CVRs) set to be issued to Bristol-Myers Squibb will get little solace from abstracts featuring Liso-cel; one of the CVR’s three triggers is Liso-cel’s approval by the end of 2020, but efficacy data from the asset’s lead indication, lymphoma, do not feature. Asco takes place from May 31 to June 4.
|Selected Asco 2019 abstracts|
|Entrectinib||Roche (ex Ignyta)||Kinase inhibitor||CNS tumours with gene mutations||10009|
|Liso-cel||Celgene/BMS||Anti-CD19 CAR-T||CLL study||7501|
|Liso-cel||Celgene/BMS||Anti-CD19 CAR-T||CRS & neurological toxicity||6637|
|AMG 510||Amgen||KRAS G12C inhibitor||First phase I data||3003|